CA2426492C - Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer - Google Patents

Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
CA2426492C
CA2426492C CA002426492A CA2426492A CA2426492C CA 2426492 C CA2426492 C CA 2426492C CA 002426492 A CA002426492 A CA 002426492A CA 2426492 A CA2426492 A CA 2426492A CA 2426492 C CA2426492 C CA 2426492C
Authority
CA
Canada
Prior art keywords
disease
alzheimer
treatment
dementia
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002426492A
Other languages
English (en)
Other versions
CA2426492A1 (fr
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28051666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2426492(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to CA002558708A priority Critical patent/CA2558708A1/fr
Publication of CA2426492A1 publication Critical patent/CA2426492A1/fr
Application granted granted Critical
Publication of CA2426492C publication Critical patent/CA2426492C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002426492A 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer Expired - Fee Related CA2426492C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002558708A CA2558708A1 (fr) 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200844 2002-05-31
DKPA200200844 2002-05-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002558708A Division CA2558708A1 (fr) 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
CA2426492A1 CA2426492A1 (fr) 2003-09-16
CA2426492C true CA2426492C (fr) 2006-10-03

Family

ID=28051666

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002426492A Expired - Fee Related CA2426492C (fr) 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer

Country Status (9)

Country Link
KR (1) KR101016927B1 (fr)
CN (1) CN1655793A (fr)
AR (1) AR040121A1 (fr)
CA (1) CA2426492C (fr)
EA (1) EA007632B1 (fr)
IS (1) IS7558A (fr)
PE (1) PE20040623A1 (fr)
UA (1) UA82480C2 (fr)
ZA (1) ZA200409147B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
CN105294450B (zh) * 2014-05-29 2024-05-17 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
WO2018062941A1 (fr) * 2016-09-30 2018-04-05 주식회사 바이오파마티스 Composition pharmaceutique pour la prévention ou le traitement d'une démence et d'un dysfonctionnement cognitif, contenant du donépézil ou un sel de qualité pharmaceutique de celui-ci et de la mémantine ou un sel de qualité pharmaceutique de celle-ci, et son procédé de préparation
KR20210072569A (ko) 2019-12-09 2021-06-17 주식회사 종근당 도네페질 및 메만틴을 포함하는 복합 제제

Also Published As

Publication number Publication date
UA82480C2 (uk) 2008-04-25
EA007632B1 (ru) 2006-12-29
IS7558A (is) 2004-11-26
PE20040623A1 (es) 2004-09-11
CN1655793A (zh) 2005-08-17
KR20050024296A (ko) 2005-03-10
ZA200409147B (en) 2006-06-28
CA2426492A1 (fr) 2003-09-16
AR040121A1 (es) 2005-03-16
KR101016927B1 (ko) 2011-02-28
EA200401617A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
EP1509232B1 (fr) Combinaison d'un antagoniste de n-methyl d-aspartate et d'inhibiteurs de l'esterase d'acetylcholine pour le traitement de la maladie d'alzheimer
AU2005219439B2 (en) 1-aminocyclohexane derivatives for the treatment of agitation and other behavioural disorders, especially those associated with alzheimer's disease
CZ290691B6 (cs) Farmaceutický prostředek
US20110172251A1 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US9839627B2 (en) Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
EA015566B1 (ru) Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая
ZA200507439B (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
RU2004101231A (ru) Таблетка, содержащая цетиризин и псевдоэфедрин
CA2426492C (fr) Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer
US4481206A (en) Spiro succinimide derivative in the treatment of dementia of the Alzheimer type
MXPA04005716A (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo.
NZ236055A (en) Use of pyrimidine-substituted piperazine derivative in the treatment of depression
CA2558708A1 (fr) Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer
JP2593910B2 (ja) パニック障害の予防又は抑制剤
JP2003523385A (ja) 神経変性疾患の治療法
KR20220020832A (ko) 단백질 감염에 사용하기 위한 3원 약학 조성물
EP0124150B1 (fr) Dérivés de benzocyclononanamine doués d'une activité anticonvulsive
WO2005097138A2 (fr) Combinaisons comprenant de l'oxcarbazepine pour le traitement de troubles affectifs
HU190714B (en) Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid
David Oxcarbazepine, Top&mate, Zonisamide, and Levetiracetam: Potential Use in Neuropathic Pain

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140508